ADMA Biologics
ADMA
ADMA
160 hedge funds and large institutions have $592M invested in ADMA Biologics in 2022 Q4 according to their latest regulatory filings, with 41 funds opening new positions, 54 increasing their positions, 38 reducing their positions, and 8 closing their positions.
New
Increased
Maintained
Reduced
Closed
more call options, than puts
Call options by funds: $ | Put options by funds: $
more first-time investments, than exits
New positions opened: | Existing positions closed:
more capital invested
Capital invested by funds: $ → $
more funds holding in top 10
Funds holding in top 10: →
42% more repeat investments, than reductions
Existing positions increased: 54 | Existing positions reduced: 38
23% more funds holding
Funds holding: 130 → 160 (+30)
4% more ownership
Funds ownership: 66.09% → 70.09% (+4%)
Holders
160
Holding in Top 10
6
Calls
$11.2M
Puts
$1.39M
Top Buyers
| 1 | +$13.9M | |
| 2 | +$10.3M | |
| 3 | +$10.1M | |
| 4 |
KCM
Kennedy Capital Management
St Louis,
Missouri
|
+$8.73M |
| 5 |
BlackRock
New York
|
+$8.25M |
Top Sellers
| 1 | -$27.4M | |
| 2 | -$6.07M | |
| 3 | -$4.92M | |
| 4 |
Nuveen Asset Management
Chicago,
Illinois
|
-$4.47M |
| 5 |
FAM
Fred Alger Management
New York
|
-$3.24M |